Qureight to highlight advances in AI-powered quantitative imaging biomarkers for respiratory clinical trials at ERS

News
23 July 2026

Qureight will present eight scientific abstracts including two oral presentations, at the ERS Congress 2026, highlighting advances in AI-powered quantitative imaging biomarkers for respiratory clinical trials. An annual event bringing together the world’s respiratory experts to showcase the latest advances in respiratory medicine and science, the ERS Congress 2026 will take place from 5–9 September in Barcelona, Spain.

Qureight to highlight advances in AI-powered quantitative imaging biomarkers for respiratory clinical trials at ERS

The presentations highlight results from multiple clinical studies demonstrating how Qureight’s enterprise-grade imaging and precision endpoints for clinical trials are enabling more sensitive and objective assessment of disease progression, helping address the limitations of conventional clinical trial endpoints.

For decades we have measured the consequences of fibrosis rather than fibrosis itself. Our data suggest that structural progression, measured directly by Computed Tomography (CT), consistently outperforms physiological surrogates such as Forced Vital Capacity (FVC) for predicting outcome, monitoring disease, and improving clinical trial efficiency. If antifibrotic therapies target fibrosis, then fibrosis—not physiology—should become the biomarker we measure. Continuing to rely primarily on FVC risks overlooking both disease progression and therapeutic benefit. By measuring fibrosis directly, we can link treatment effects more closely to the structural disease process that shapes how patients feel, function, and survive.

Dr Simon Walsh

Chief Scientific Officer

The presentations build on Qureight's growing role as an imaging CRO supporting global respiratory clinical trials. By combining expert imaging operations with AI-powered quantitative analysis, Qureight helps sponsors generate robust imaging endpoints, improve disease characterisation and gain deeper insights into treatment response.

The posters and oral presentations explore four key themes:

Imaging Biomarkers - the Future of Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial Endpoints

  • Quantitative CT can provide a more sensitive and efficient endpoint than FVC, in respiratory disease, through demonstrating lower variance and improved trial efficiency.

Longitudinal Imaging Outperforms Conventional Disease Monitoring

  • Understanding structural progression through longitudinal CT imaging in respiratory disease can provide further insights than just physiology alone, identifying high-risk patients that FVC in isolation is unable to detect.

Extending Quantitative CT Beyond IPF

  • Advanced AI-imaging analytic platforms have shown promise in IPF. These imaging biomarkers have also successfully phenotyped disease and predicted outcomes in Connective Tissue Disease associated Interstitial Lung Disease, showing their potential across fibrotic lung diseases.

Platform Expansion and Clinical Trial Partnerships

  • Imaging biomarkers are becoming increasingly important across respiratory disease clinical trials, particularly as these can also support pulmonary vascular disease in addition to fibrotic respiratory diseases. These models are therefore becoming more widely adopted in industry-sponsored clinical trials.

Qureight’s Scientific programme at the ERS Congress 2026:

Poster: Trial efficiency gains using quantitative CT fibrosis compared with FVC in idiopathic pulmonary fibrosis

  • Date: 6 September, 8:00 – 9:30am CEST
  • Location: PS-42

Poster: Study Design and Baseline Characteristics of AURORA, a Randomised Placebo-Controlled Double-Blind Study of CAL101 in IPF

  • Date: 6 September, 08:00 – 09:30am, CEST
  • Location: PS-34

Poster: Longitudinal quantitative CT change outperforms baseline imaging burden for mortality prediction in idiopathic pulmonary fibrosis

  • Date: 6 September, 12:30 – 2:00pm, CEST
  • Location: PS-37

Poster: Longitudinal quantitative CT detects high-risk disease progression in idiopathic pulmonary fibrosis despite stable lung function

  • Date: 7 September, 12:30 – 14:00pm, CEST
  • Location: PS-42

Oral presentation: Anthropometry, Sex, and Age at Diagnosis Affect AI-Based Pulmonary Blood Volume Quantification from CTPA in Pulmonary Hypertension

  • Date: 7 September, 16:10 – 16:15pm CEST
  • Location: Room 3I

Oral presentation: Quantitative CT Fibrosis More Accurately Captures Phenotype and Prognosis in Connective Tissue Disease–Related ILD

  • Date: 7 September, 16:25 – 16:30pm CEST
  • Location: Room 3I

Poster: Minimal Clinically Important Difference of a High-Resolution Computed Tomography Biomarker of Lung Fibrosis Based on a 3D Convolutional Neural Network Segmentation Algorithm

  • Date: 8 September, 8:00 – 9:30am CEST
  • Location: PS-36

Poster: Improvement of three-year mortality prediction for idiopathic pulmonary fibrosis based on the inclusion of high-resolution computed tomography for lung function change features

  • Date: 8 September, 8:00 – 09:30am, CEST
  • Location: PS-36